Drug Trial Radar · NCT07379125
Therapeutic RSK1 Targeting in Myeloid Malignancies
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
May 20, 2026
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Phoenix Molecular Designs; The Foundation for Barnes-Jewish Hospital; Swim Across America; Blood Cancer United
- First posted
- Jan 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study hypothesizes that PMD-026, an oral inhibitor of ribosomal protein S6 kinase A1 (RSK1), is safe and well tolerated in participants with myelofibrosis (MF) and myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPNs) and will improve spleen response, symptom response, and bone marrow histopathological response.
Conditions
- Myeloid Malignancy
Interventions
PMD-026Drug
PMD-026 is an oral drug which will be taken every 12 hours on an outpatient basis at the assigned dose every day of each 28-day cycle. Provided by Phoenix Molecular Designs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse eventsTime frame: From cycle 1 day 1 through 28 days after last dose (estimated to be 1 year and 28 days)
- Number of participants with dose limiting toxicities (DLTs) based on occurrence of serious treatment-emergent adverse events (Dose Escalation only)Time frame: During cycle 1 of treatment (each cycle is 28 days)
- Recommended phase II dose (RP2D) (Dose Escalation only)Time frame: Completion of cycle 1 (each cycle is 28 days) of all dose-escalation patients (estimated to be 1 year and 28 days)
- Changes in spleen size (Dose Expansion and RP2D Cohort in Dose Escalation)Time frame: Baseline and after 24 weeks of treatment (estimated to be 24 weeks)
- Changes in Myelofibrosis Symptom Assessment Form (MFSAF) v4.0 Total Symptom Score (Dose Expansion and PR2D Cohort in Dose Escalation)Time frame: Baseline and after 24 weeks of treatment (estimated to be 24 weeks)
- Bone marrow histopathologic response (Dose Expansion and RP2D Cohort in Dose Escalation)Time frame: Baseline and after 24 weeks of treatment (estimated to be 24 weeks)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Washington University School of Medicine
St Louis, Missouri · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.